+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

One-year follow-up of combined customized therapy. Photodynamic therapy and bevacizumab for exudative age-related macular degeneration



One-year follow-up of combined customized therapy. Photodynamic therapy and bevacizumab for exudative age-related macular degeneration



Retina 29(1): 13-19



To evaluate whether combined, personalised photodynamic therapy (PDT) and Bevacizumab in choroidal neovascularization associated with age-related macular degeneration can improve vision, and whether it is possible to decrease the frequency and number of intravitreal antiangiogenics. A prospective, noncomparative, interventional study of a case series of 63 patients with exudative age-related macular degeneration, treated with an initial dose of PDT and intravitreal Bevacizumab 24 to 48 hours afterwards. Retreatments were carried out as required with monthly Bevacizumab and PDT every 3 months if there were relapses. Follow-up lasted 1 year in all cases. After the first month of treatment, the mean best-corrected visual acuity increased by 4.85 letters, reaching 5.65 letters at the 12-month follow-up (P < 0.05). Compared with initial vision, 79.3% of the eyes had the same or better vision and 95.2% lost fewer than 15 letters. The total number of PDT treatments was 92 (a mean of 1.46 treatments per patient). The mean number of Bevacizumab injections was two per patient. In 29 cases (46%), only one initial treatment with PDT + Bevacizumab was necessary. In 15 cases (23.8%), more than two combined treatments per patient were necessary. Combined, customized PDT + Bevacizumab therapy makes it possible to obtain visual results similar to those obtained in monotherapy, but with fewer intravitreal injections. It appears to be an interesting option for this type of patients.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 054750769

Download citation: RISBibTeXText

PMID: 18854782

DOI: 10.1097/iae.0b013e31818a1fd3


Related references

Combined therapy (intravitreal bevacizumab plus verteporfin photodynamic therapy) versus intravitreal bevacizumab monotherapy for choroidal neovascularization due to age-related macular degeneration: a 1-year follow-up study. Digital Journal of Ophthalmology 22(2): 46-53, 2016

Combination therapy in exudative age-related macular degeneration: visual outcomes following combined treatment with photodynamic therapy and intravitreal bevacizumab. Canadian Journal of Ophthalmology. Journal Canadien d'Ophtalmologie 45(4): 375-380, 2010

Photodynamic therapy with verteporfin combined with intravitreal injection of bevacizumab for exudative age-related macular degeneration. Acta Ophthalmologica Scandinavica 84(6): 831-833, 2006

Intravitreal bevacizumab alone versus combined verteporfin photodynamic therapy and intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration: visual acuity after 1 year of follow-up. Retina 30(4): 548-554, 2010

One-year results of photodynamic therapy combined with intravitreal ranibizumab for exudative age-related macular degeneration. Journal of Ophthalmology 2012: 154659, 2012

Comparison of different treatment intervals between bevacizumab injection and photodynamic therapy in combined therapy for age-related macular degeneration. Japanese Journal of Ophthalmology 56(5): 470-475, 2012

One-year results of combined photodynamic therapy and intravitreal bevacizumab injection for retinal pigment epithelial detachment secondary to age-related macular degeneration. Graefe's Archive for Clinical and Experimental Ophthalmology 247(7): 899-906, 2009

Triple therapy for neovascular age-related macular degeneration using single-session photodynamic therapy combined with intravitreal bevacizumab and triamcinolone. British Journal of Ophthalmology 93(6): 754-758, 2009

Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: meta-analysis of 2-year safety results in three randomized clinical trials: Treatment Of Age-Related Macular Degeneration With Photodynamic Therapy and Verteporfin In Photodynamic Therapy Study Report no. 4. Retina 24(1): 1-12, 2004

Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Archives of Ophthalmology 117(10): 1329-1345, 1999

Prospective comparison of low-fluence photodynamic therapy combined with intravitreal bevacizumab versus bevacizumab monotherapy for choroidal neovascularization in age-related macular degeneration. Seminars in Ophthalmology 30(2): 112-117, 2015

Combined treatment of exudative age related macular degeneration with photodynamic therapy and intravitreal triamcinolone. Clinical Ophthalmology 2(1): 71-75, 2008

Combined intravitreal bevacizumab and photodynamic therapy for neovascular age-related macular degeneration. Graefe's Archive for Clinical and Experimental Ophthalmology 246(1): 17-25, 2008

Treatment of Exudative Age-Related Macular Degeneration with Ranibizumab Combined with Ketorolac Eyedrops or Photodynamic Therapy. Retina 35(8): 1547-1554, 2015

Verteporfin photodynamic therapy combined with intravitreal bevacizumab for neovascular age-related macular degeneration. Ophthalmology 116(4): 747, 2009